Dihexa
Peptide therapy: benefits, side effects, cost and protocols
C27H44N4O5
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an oligopeptide drug derived from angiotensin IV that has been found to be a potent cognitive enhancer in animal models. It acts as a hepatocyte growth factor (HGF) receptor agonist and has shown the ability to cross the blood-brain barrier.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Banned from Compounding March 2024 Not eligible for compounding. Removed from bulk drug substance nomination list.
- Evidence
- Emerging Evidence
Who it's for
Who Dihexa is usually considered for
- Cognitive enhancement
- Memory improvement
- Neuroplasticity support
- Neuroprotection
- 1 preclinical study
- Learning enhancement
- Primarily animal or early-phase data
Mechanism
How Dihexa works
Binds to hepatocyte growth factor (HGF) receptor, dramatically increasing its activity. This promotes synaptogenesis, neuronal survival, and neuroplasticity through the HGF/c-Met pathway.
Evidence
Key studies
19 papers on PubMed
- 01
Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies
Neurosci Biobehav Rev / Neurosci Biobehav Rev
- 02
Angiotensin IV and analogs improved cognitive performance in normal and impaired animal models
- 03
Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats
- 04
Wells RG, Azzam AF, Hiller AL et al
J Huntingtons Dis / Animal
PNB-0408 did not protect rats from 3-NP-induced Huntington's disease-like symptoms.
- 05
PNB-0408 did not protect rats from 3-NP-induced Huntington's disease-like symptoms
- 06
The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system
- 07
Benoist CC, Kawas LH, Zhu M et al
J Pharmacol Exp Ther / Animal
- 08
Dihexa's procognitive activity depends on HGF/c-Met system activation
- 09
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
J Am Acad Orthop Surg Glob Res Rev
- 10
Therapeutic peptides modulate tissue regeneration and neuroplasticity pathways in orthopaedic applications
Compound
Dihexa compound data
- Formula
- C27H44N4O5
- Mol. weight
- 504.7 g/mol
- PubChem CID
- 129010512 ↗
- IUPAC
- (2S,3S)-N-(6-amino-6-oxo-hexyl)-2-[[(2S)-2-(hexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-methyl-pentanamide
FAQ
Dihexa questions
What is DIHEXA?
Dihexa is a potent nootropic peptide derived from angiotensin IV, researched for its remarkable ability to enhance cognitive function and promote neuroplasticity. It is considered one of the most powerful cognitive-enhancing peptides studied.
How does DIHEXA work?
Binds to hepatocyte growth factor (HGF) receptor, dramatically increasing its activity. This promotes synaptogenesis, neuronal survival, and neuroplasticity through the HGF/c-Met pathway.
Is DIHEXA legal to buy?
DIHEXA is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy DIHEXA?
DIHEXA is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does DIHEXA belong to?
DIHEXA is primarily classified as a cognitive enhancement peptide. Nootropic peptides researched for cognitive function, memory, focus, neuroprotection, and neurogenesis.
What are the research benefits of DIHEXA?
DIHEXA has been studied for: Cognitive enhancement, Memory improvement, Neuroplasticity support, Neuroprotection, Learning enhancement. Extremely potent nootropic; 10 million times more potent than BDNF in some assays.
News
Dihexa in the news
Umbrella Lab Announces Documentation And Traceability Update For Dihexa Peptide - The Daily Tribune News
The Daily Tribune News / 1 month ago
Drug that shifts brain’s signaling balance could treat autism - The Transmitter
The Transmitter / 29 months ago
Everything You Need to Know About the FDA Peptide Ban - Hone Health
Hone Health / 31 months ago
FDA panel will meet to discuss allowing broader access to certain peptides - STAT
STAT / 5 months ago
RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban - Ars Technica
Ars Technica / 5 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Dihexa?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.